JP Morgan Chase’s NovoCure NVCR Stock Holding History

JP Morgan Chase’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-157,800	Closed	-$2.47M	–	7625
2024 Q3	$2.47M	Buy	+157,800	New	+$2.86M	﹤0.01%	3840
2023 Q1	–	Sell	-77,200	Closed	-$5.66M	–	7076
2022 Q4	$5.66M	Buy	77,200 +75,500	+4,441%	+$5.68M	﹤0.01%	2720
2022 Q3	$129K	Buy	1,700 +400	+31%	+$31.2K	﹤0.01%	5170
2022 Q2	$90K	Sell	1,300 -75,200	-98%	-$5.66M	﹤0.01%	5462
2022 Q1	$6.34M	Buy	+76,500	New	+$5.64M	﹤0.01%	2802
2021 Q4	–	Sell	-1,000	Closed	-$116K	–	6862
2021 Q3	$116K	Buy	+1,000	New	+$151K	﹤0.01%	5496
2021 Q1	–	Sell	-60,000	Closed	-$10.4M	–	6255
2020 Q4	$10.4M	Buy	+60,000	New	+$8.21M	﹤0.01%	2188
2020 Q2	–	Sell	-20,000	Closed	-$1.35M	–	5595
2020 Q1	$1.35M	Buy	+20,000	New	+$1.58M	﹤0.01%	3228

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

JP Morgan Chase's NVCR Position: Q2 2026 in Review

JP Morgan Chase increased its NovoCure (NVCR) stake by 80% in Q2 2026, buying an estimated $11.2M and bringing the position to 1,671,082 shares worth $25.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1991.

JP Morgan Chase first reported a position in NVCR in Q4 2015 and has held it in 37 quarters since. The position peaked at $31.9M in Q4 2020. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

JP Morgan Chase held 1,671,082 shares of NovoCure worth $25.9M as of Q2 2026.
JP Morgan Chase bought 740,916 NovoCure shares in Q2 2026, an estimated $11.2M.
NovoCure made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #1991 holding.
JP Morgan Chase first reported a position in NovoCure in Q4 2015 and has held it in 37 quarters since.
JP Morgan Chase's NovoCure position peaked at $31.9M in Q4 2020.
218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.